Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal

March 31, 2026 1:28 PM
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $246.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "Today, BIIB ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments